Biovica International AB (publ) (BIOVIC-B.ST)
SEK 0.73
(4.0%)
SEK 0.73
(4.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -119.5 Million SEK | -18.71% |
| 2022 | -105.96 Million SEK | -87.8% |
| 2021 | -53.47 Million SEK | -64.55% |
| 2020 | -36.56 Million SEK | -29.39% |
| 2019 | -25.64 Million SEK | -37.19% |
| 2018 | -18.5 Million SEK | -22.84% |
| 2017 | -15.21 Million SEK | -16.85% |
| 2016 | -13.02 Million SEK | -302.57% |
| 2015 | -4.16 Million SEK | 37.54% |
| 2014 | -5.17 Million SEK | -29.51% |
| 2013 | -3.99 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -20.98 Million SEK | 45.34% |
| 2023 FY | - SEK | -18.71% |
| 2023 Q3 | -25.09 Million SEK | -19.98% |
| 2023 Q1 | -29.4 Million SEK | 17.0% |
| 2023 Q2 | -20.91 Million SEK | 28.85% |
| 2023 Q4 | -39.11 Million SEK | -55.82% |
| 2022 Q2 | -21.31 Million SEK | -14.59% |
| 2022 FY | - SEK | -87.8% |
| 2022 Q4 | -35.42 Million SEK | -30.05% |
| 2022 Q3 | -27.24 Million SEK | -27.81% |
| 2022 Q1 | -18.6 Million SEK | -8.03% |
| 2021 Q2 | -12.77 Million SEK | -19.93% |
| 2021 FY | - SEK | -64.55% |
| 2021 Q1 | -10.65 Million SEK | -4.55% |
| 2021 Q4 | -17.21 Million SEK | -23.22% |
| 2021 Q3 | -13.97 Million SEK | -9.38% |
| 2020 FY | - SEK | -29.39% |
| 2020 Q2 | -5.59 Million SEK | 32.89% |
| 2020 Q3 | -9.18 Million SEK | -64.09% |
| 2020 Q4 | -10.18 Million SEK | -10.91% |
| 2020 Q1 | -8.34 Million SEK | -1.57% |
| 2019 Q2 | -4.68 Million SEK | 11.85% |
| 2019 Q3 | -7.04 Million SEK | -50.53% |
| 2019 Q1 | -5.3 Million SEK | 1.19% |
| 2019 FY | - SEK | -37.19% |
| 2019 Q4 | -8.21 Million SEK | -16.56% |
| 2018 Q1 | -3.21 Million SEK | 5.88% |
| 2018 FY | - SEK | -22.84% |
| 2018 Q4 | -5.37 Million SEK | -8.63% |
| 2018 Q3 | -4.94 Million SEK | -1.21% |
| 2018 Q2 | -4.88 Million SEK | -52.01% |
| 2017 Q2 | -3.84 Million SEK | -42.9% |
| 2017 Q1 | -2.69 Million SEK | 49.27% |
| 2017 FY | - SEK | -16.85% |
| 2017 Q4 | -3.41 Million SEK | 35.11% |
| 2017 Q3 | -5.26 Million SEK | -36.83% |
| 2016 Q3 | -3.64 Million SEK | -56.6% |
| 2016 FY | - SEK | -302.57% |
| 2016 Q4 | -5.3 Million SEK | -45.64% |
| 2016 Q2 | -2.32 Million SEK | -33.35% |
| 2016 Q1 | -1.74 Million SEK | 15.73% |
| 2015 Q4 | -2.07 Million SEK | -5.49% |
| 2015 Q2 | -216.5 Thousand SEK | 0.0% |
| 2015 Q1 | -216.5 Thousand SEK | 0.0% |
| 2015 FY | - SEK | 37.54% |
| 2015 Q3 | -1.96 Million SEK | -806.7% |
| 2014 FY | - SEK | -29.51% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alzinova AB (publ) | 41.99 Thousand SEK | 284644.87% |
| Amniotics AB (publ) | -27.14 Million SEK | -340.283% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -740.585% |
| BioArctic AB (publ) | 275.38 Million SEK | 143.396% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 67.508% |
| Camurus AB (publ) | 562.54 Million SEK | 121.244% |
| Cantargia AB (publ) | -284.31 Million SEK | 57.967% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -510.378% |
| Genovis AB (publ.) | 64.57 Million SEK | 285.074% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -4.002% |
| Mendus AB (publ) | -97.84 Million SEK | -22.137% |
| Kancera AB (publ) | -61.88 Million SEK | -93.097% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -346.201% |
| LIDDS AB (publ) | -39.67 Million SEK | -201.25% |
| Lipum AB (publ) | -37.11 Million SEK | -221.954% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -887.327% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 480.544% |
| NextCell Pharma AB | -40.98 Million SEK | -191.584% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1744.729% |
| Saniona AB (publ) | -69.69 Million SEK | -71.47% |
| Simris Alg AB (publ) | -22.36 Million SEK | -434.392% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 62.356% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 57.627% |
| Xintela AB (publ) | -53.47 Million SEK | -123.497% |
| Ziccum AB (publ) | -20.34 Million SEK | -487.484% |
| AcouSort AB (publ) | -16.7 Million SEK | -615.476% |
| Active Biotech AB (publ) | -43.88 Million SEK | -172.304% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -599.499% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 5975400.0% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -222.78% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 29.626% |
| CombiGene AB (publ) | -35.33 Million SEK | -238.198% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 15.154% |
| Intervacc AB (publ) | -68.98 Million SEK | -73.247% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 49.706% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -5645.481% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -789.777% |
| Corline Biomedical AB | -1.69 Million SEK | -6967.179% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 31.051% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -118.053% |
| Aptahem AB (publ) | -10 Million SEK | -1093.958% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 1134.774% |
| Fluicell AB (publ) | -25.91 Million SEK | -361.164% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -183.029% |
| Abliva AB (publ) | -93.6 Million SEK | -27.666% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 62.549% |
| 2cureX AB (publ) | -35.13 Million SEK | -240.124% |
| I-Tech AB | 30.34 Million SEK | 493.824% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 83.275% |
| Cyxone AB (publ) | -20.41 Million SEK | -485.412% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -16.645% |
| Biosergen AB | 228 Thousand SEK | 52514.912% |
| Nanologica AB (publ) | -62.11 Million SEK | -92.382% |
| SynAct Pharma AB | -222.7 Million SEK | 46.338% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -172.465% |
| BioInvent International AB (publ) | -312.7 Million SEK | 61.783% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 38723.458% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 48.405% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1256.1% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -10.085% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -941.991% |